Retrospective clinical studies have highlighted the significance of CD47 in glioma patients, observing that patients with lower overall survival rates expressed higher levels of CD47 and the expression levels inversely correlated with histopathologic grading [74]. This evidence concerns the gene CD47 and central nervous system cancer.